Third-look endoscopy prevents delayed bleeding after endoscopic submucosal dissection under antithrombotic therapy

Table 4 Baseline characteristics of the third-look endoscopy and control group after propensity score matching

	TLE (n = 58)	Control (n = 58)	P value
Age, mean ± SD (yr)	75.8 ± 6.4	77.7 ± 6.5	0.10
Sex			0.59
Male, % (n)	84.5 (49)	87.9 (51)
Female, % (n)	15.5 (9)	12.1 (7)
Location-1			0.52
Upper, % (n)	19.0 (11)	13.8 (8)
Middle, % (n)	6.9 (4)	12.1 (7)
Lower, % (n)	74.1 (43)	74.1 (43)
Location-2			0.14
Anterior wall, % (n)	12.1 (7)	24.1 (14)
Posterior wall, % (n)	34.5 (20)	19.0 (11)
Lesser curvature, % (n)	34.5 (20)	41.4 (24)
Greater curvature, % (n)	19.0 (11)	15.5 (9)
Morphology			0.35
Protruded, % (n)	46.6 (27)	55.2 (32)
Flat/depressed, % (n)	53.5 (31)	44.8 (26)
Median tumor size (range)	9.5 (2-40)	11.0 (3-43)	0.54
Median specimen size (range)	34 (18-60)	33 (17-78)	0.71
Ulcerative findings			1.00
(+), % (n)	1.7 (1)	1.7 (1)
(-), % (n)	98.3 (57)	98.3 (57)
Depth of invasion			0.17
M/SM1, % (n)	98.3 (57)	93.1 (54)
SM2-, % (n)	1.7 (1)	6.9 (4)
Pathological finding			-
Differentiated type, % (n)	100 (58)	100 (58)
Undifferentiated type, % (n)	0 (0)	0 (0)
Lymphovascular infiltration			1.00
(+), % (n)	3.5 (2)	3.5 (2)
(-), % (n)	96.6 (56)	96.6 (56)
Median procedure time (range)	36.0 (10-78)	37.0 (8-175)	0.14
Receiving antithrombotic agents			-
Continue, % (n)	100 (58)	100 (58)
Discontinue, % (n)	0 (0)	0 (0)

TLE: Third-look endoscopy; M: Mucosa; SM1: Submucosa (-500 μm); SM2-: Submucosa (500 μm-).